info@marketresearchfuture.com   📞  +1 (855) 661-4441(US)   📞  +44 1720 412 167(UK)
Certified Global Research Member
Isomar fd.webp Wcrc 57.webp
Key Questions Answered
  • Global Market Outlook
  • In-depth analysis of global and regional trends
  • Analyze and identify the major players in the market, their market share, key developments, etc.
  • To understand the capability of the major players based on products offered, financials, and strategies.
  • Identify disrupting products, companies, and trends.
  • To identify opportunities in the market.
  • Analyze the key challenges in the market.
  • Analyze the regional penetration of players, products, and services in the market.
  • Comparison of major players’ financial performance.
  • Evaluate strategies adopted by major players.
  • Recommendations
Why Choose Market Research Future?
  • Vigorous research methodologies for specific market.
  • Knowledge partners across the globe
  • Large network of partner consultants.
  • Ever-increasing/ Escalating data base with quarterly monitoring of various markets
  • Trusted by fortune 500 companies/startups/ universities/organizations
  • Large database of 5000+ markets reports.
  • Effective and prompt pre- and post-sales support.

Primary Ciliary Dyskinesia Companies

Primary Ciliary Dyskinesia (PCD) is a rare genetic disorder characterized by impaired function of cilia, which are tiny hair-like structures that play a crucial role in moving mucus and maintaining respiratory health. While there may not be specific companies exclusively focused on PCD, various pharmaceutical and biotechnology companies may be involved in research, development, and potential treatments related to respiratory disorders, including PCD. Additionally, diagnostic companies may contribute to the identification and diagnosis of PCD.

Primary Ciliary Dyskinesia Key Companies

 

Latest Primary Ciliary Dyskinesia Companies Update


Parion Pharmaceuticals announces positive results from a Phase 2 clinical trial of inhaled idrevloride with hypertonic saline for treating PCD, demonstrating improvements in lung function and mucociliary clearance


Shire (Takeda) receives FDA approval for Pulmozyme® (dornase alfa), expanding treatment options for PCD patients struggling with chronic respiratory infections.Aerocrine introduces the SpiroSonic® NO Meter, a portable device for measuring nitric oxide levels in exhaled breath, potentially aiding in PCD diagnosis and monitoring


The PCD Foundation partners with pharmaceutical companies and research institutions to accelerate clinical trials and development of new treatments for PCD.


Cystic Fibrosis Foundation Therapeutics (CFFT) collaborates with researchers to explore potential synergies between PCD and cystic fibrosis therapies, benefiting both patient populations.


List of Primary Ciliary Dyskinesia Key Companies in the Market



  • AstraZeneca

  • Boehringer Ingelheim GmbH

  • GlaxoSmithKline

  • Novartis AG

  • Pfizer Inc.

  • Teva UK Limited

  • Masimo Corporation (U.S.)

  • BD (U.S.)

  • Portex Division of Smith Industries Medical System

  • Teruma Medical Corporation

  • HTL STREFA SA

  • Greinier Bio One International GmBH.

  • Hoffman La Roche AG

  • Bayer AG.

  • Acare Technology Co.

  • Medline Industries Inc.Ltd.

  • Hill-Rom Holdings Inc.

  • Allied Healthcare Inc.

  • Rotech Healthcare Inc


Leading companies partner with us for data-driven Insights
client_1 client_2 client_3 client_4 client_5 client_6 client_7 client_8 client_9 client_10
Kindly complete the form below to receive a free sample of this Report
Please fill in Business Email for Quick Response

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Purchase Option
Single User $ 4,950
Multiuser License $ 5,950
Enterprise User $ 7,250
Compare Licenses
Tailored for You
  • Dedicated Research on any specifics segment or region.
  • Focused Research on specific players in the market.
  • Custom Report based only on your requirements.
  • Flexibility to add or subtract any chapter in the study.
  • Historic data from 2014 and forecasts outlook till 2040.
  • Flexibility of providing data/insights in formats (PDF, PPT, Excel).
  • Provide cross segmentation in applicable scenario/markets.